BACKGROUND Chimeric antigen receptor (CAR) T cell immunotherapy has resulted in
complete remission (CR) and durable response in highly refractory patients. However …

BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs)
improve outcomes for CD19-expressing B cell malignancies. We evaluated a human …

The past several years have been marked by extraordinary advances in clinical applications
of immunotherapy. In particular, adoptive cellular therapy utilizing chimeric antigen receptor …

Chimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for
refractory and relapsed leukemia patients and is also emerging as a potential therapeutic …

Adoptive transfer of T cells expressing a CD19-specific chimeric antigen receptor (CAR) is
being evaluated in multiple clinical trials. Our current approach to adoptive immunotherapy …

Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in
achieving a complete remission in a range of B-cell malignancies, most notably B-acute …

Immunotherapy with T cell modified with gamma-retroviral or lentiviral (LV) vectors to
express a chimeric antigen receptor (CAR) has shown remarkable efficacy in clinical trials …

Chimeric antigen receptors (CARs) have shown remarkable ability to re-direct T cells to
target CD19-expressing tumours, resulting in remission rates of up to 90% in individuals with …

Opinion statement Adoptive transfer of autologous T cells engineered to express a chimeric
antigen receptor (CAR) represents a powerful targeted immunotherapy that has shown great …

CD19-specific chimeric antigen receptor (CAR19) T-cells effectively induce remission of B-
cell malignancy, but the cost and complexity of production using viral vectors is a factor …